DOCSLIB.ORG

Pathophysiological Responses to Meals in the Zollinger-Ellison Syndrome: 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pathophysiological Responses to Meals in the Zollinger-Ellison Syndrome: 2 Gut: first published as 10.1136/gut.21.2.98 on 1 February 1980. Downloaded from Gut, 1980, 21, 98-104 Pathophysiological responses to meals in the Zollinger-Ellison syndrome: 2. Gastric emptying and its effect on duodenal function* J-R MALAGELADAt From the Gastroenterology Unit, Mayo Clinic and Mayo Foundation, Rochester, MN, USA SUMMARY In this study, wc investigated the relationship between gastric emptying and duodenal events in patients with the Zollinger-Ellison syndrome due to a gastrinoma. Like the inhibitory effect of a meal on gastric secretion (described in a companion paper), postprandial inhibition of gastric emptying reduces fractional gastric emptying rates to normal during the first two hours after a meal. Gastric discharges of content into the duodenum fluctuate considerably, and, in some patients, duodenal acid load and neutralising duodenal secretions appear to be incoordinated. These mechanisms interact in part as a protective system that maintains reasonably normal duo- denal homeostasis in most Zollinger-Ellison patients during the early postprandial period. Our data may expJain why clinical evidence of overt-malabsorption is less prevalent and severe in these patients than would be expected from their enormously increased fasting gastric secretory outputs. Diarrhoea and steatorrhoea are common features of meal and gastric juice, presumably a key patho- of the Zollinger-Ellison syndrome and sometimes genetic factor, has not been quantified. http://gut.bmj.com/ its only clinical manifestations. It is generally In the first paper of this series7 we showed that assumed that they result from the alteration in profound variations of gastric secretory output intraluminal digestion in the upper gut caused by occur postprandially in patients with gastrinoma. gastric emptying of large volumes of highly acidic Thus, it cannot be assumed that the conventional gastric juice. Moreover, several specific disturbances basal acid output or maximal acid output measure- have been identified-among others, acid inactiva- ments also represent the secretory output after a tion of pancreatic enzymes, precipitation of un- meal or, even less so, the postprandial rate of acid on September 29, 2021 by guest. Protected copyright. ionised bile acids, dilution of duodenal contents, delivery into the duodenum. Using intubation and and, possibly, damage to the intestinal mucosa.'-" perfusion techniques developed in our laboratory, In spite of the progress made, our knowledge of we evaluated, in an integrated fashion, the effects of digestive disturbances in the Zollinger-Ellison syn- postprandial gastric emptying on pancreatic, biliary, drome is still fragmentary and incomplete because and intestinal function. Our goal has been to improve (1) only isolated cases of the syndrome have been our understanding of the mechanisms of disturbed studied by any group of investigators, and these intraluminal digestion and diarrhoea in patients case reports do not indicate whether the abnorma- with the Zollinger-Ellison syndrome. lities observed are exceptional or the rule; (2) most of the measurements have been of concentrations Methods of either endogenously secreted or ingested sub- stances without quantification of intraluminal flow PATIENTS or total secretory outputs; and (3) gastric emptying Six patients (two females and four males, aged 13 to 63 years, with a mean of 40-1 years) with the Zollinger-Ellison syndrome were studied. All ful- *Supported in part by Grant AM-6908 from the National Institutes of Health. filled the criteria of fasting gastric hyperchlorhydria, tAddress for reprint requests: DrJ-R Malagelada, Gastro- hypergastrinaemia, and, later, surgically proved enterology Unit, Mayo Clinic, Rochester, MN 55901 gastrinoma. All were normocalcaemic, and none US4. had had gastric surgery before studies were per- Received for publication 10 August 1979 formed. Individual clinical histories and gastric 98 Gut: first published as 10.1136/gut.21.2.98 on 1 February 1980. Downloaded from Pathophysiological responses to meals in the Zollinger-Ellison syndrome 99 secretory data were reported in the first paper of this into the duodenum at rates (about 600 ml/h, as an series.7 Two patients were restudied after successful average) similar to those of their fasting gastric excision of their gastrinomas (duodenal wall tumour secretory output7, an indlcation that the steady- in both instances) without other surgical procedures. state conditions between gastric secretion and empty- Six healthy volunteers (two women and four men, ing that prevail in the interdigestive period had aged 22 to 63 years, with a mean of 39.7±7.1 returned. At that time, three hours after the meal, years) were similarly studied as controls. intragastric volume was similar in healthy persons in Zollinger-Ellison patients despite quite different QUANTIFICATION OF POSTPRANDIAL GASTRIC emptying rates. This discrepancy is reflected in the EMPTYING, PANCREATIC AND BILIARY fractional gastric emptying rate-that is, the per- SECRETION, AND INTESTINAL FLOW centage of intragastric contents emptied per unit of We used our methods for the quantification of time. Fractional gastric emptying was similar in gastric secretory outputs, gastric emptying of meal Zollinger-Ellison patients and in healthy persons and secretions, pancreatic enzyme and biliary during the first two postprandial hours but during outputs, and total duodenal flow8-10. In the first the third hour it was significantly higher in the former paper of this series7 I have described the pertinent (p<0.05). methodological details. In addition, intestinal samples were analysed for pH, osmolality, trypsin FLOW AT LIGAMENT OF TREITZ AND ITS and lipase activities, and total bile acids by methods RELATIONSHIP TO GASTRIC EMPTYING also previously described.8-'0 In previously reported Intraluminal flow measured at the ligament of studies'" we showed that the presence of the trans- Treitz represents the net volume load (gastric duodenal tube does not significantly alter the rate emptying plus pancreatic, biliary, and duodenal of gastric emptying. Two patients whose tumours secretions minus duodenal absorption) delivered were resected and whose fasting serum gastrin into the jejunum. Flow profiles (Fig. 2) in Zollinger- levels returned to normal after the procedure were Ellison patients were quite different from those in restudied after the fourth postoperative week. healthy controls. The highest flow rates in the healthy persons were reached during the first postprandial Results hour, whereas just the opposite was observed in the Zollinger-Ellison patients. During the second and http://gut.bmj.com/ GASTRIC EMPTYING (Fig. 1) third hours, flow rates were much higher in the During the first postprandial hour, the total volume patients than in the controls (p< 005). of gastric contents (meal and gastric secretion) The influence of gastric emptying on jejunal emptied into the duodenum was similar in healthy volume loads in the Zollinger-Ellison syndrome can controls and in patients with Zollinger-Ellison be appreciated in Fig. 3, where we have compared, syndrome. Thereafter, the volume emptied gradually in each individual, the volume delivered by the decreased in the healthy persons but continued stomach during the three-hour observation period on September 29, 2021 by guest. Protected copyright. increasing in the patients. By the third postprandial with the volume passing the ligament of Treitz hour, gastric juice in the patients was being delivered during the same period. It is apparent that gastric HEALTH ZOLLINGER-ELLISON 120 _ 400 _ Fig. 1 Total volume ofgastric contents empticd into duodenum 80 - after meals, including meal itself (clear area) andaddedgastric mi/lomin 60 - secretion (shaded area). Mean values every 10 minutes aregiven 40 - for healthy controls (left panel) andfor patients with Zollinger- 20 Ellison syndrome (right panel). 0 0 4 2 3 4 0 4 2 3 4 Meal Meal Hours Hours fT Gut: first published as 10.1136/gut.21.2.98 on 1 February 1980. Downloaded from 100 Malagedads Volume flow at ligament Fig. 2 Intraduodenalflow after meals in healthy persons and in patients with of Treitz, Zollinger-Ellison syndrome. Note different mi/10 min profiles between patients and controls: flow rates informer are highest during /ate postprandialperiod, whereas opposite is true. for healthy individuals. O 1 2 3 T Meal Hours emptying is a major determinant of jejunal volume Table 1 Peak postprandial outputs ofpancreatic enzymes load in these patients with Zollinger-Ellison syn- andbile acids drome. This is so because duodenal absorption Peak output* cannot increase enough to compensate for increased Patients fluid emptied and, consequently, flow at the liga- with Trypsin Lipase, Bile acids Z-E (kU/min) (kU/min) (vmol/min) http://gut.bmj.com/ ment of Treitz increases linearly with the absolute rate of gastric emptying. In two patients restudied 1 596 2163 97-1 2 831 3432 81-3 after successful excision of their gastrin-producing 3 1269 1659 79.3 4 1004 4387 53.0 3 5 494 1363 38-1 6 457 1397 45 3 Mean±SE 775 + 131 2400±507 657+-9-6 it 380 2574 48-7 2t 1232 4425 42.5 on September 29, 2021 by guest. Protected copyright. Mean±SE 942 107 2503±283 53.0±5.6 2 0 in 6 Volume of healthy persons gastric contents a O emptied, *Highest three consecutive 10-minute periods. tRepeat studies after excision of gastrin producing tumour. L /3 h 1 .x Table 2 Effect of excision ofgastrinoma on postprandial *0& duodenal events 1 Patient 2 n- - Patient u 3 l 2 Measurement Preop Postop Preop Postop Volume flow at ligament of Treitz, 1 /3 h Lowest duodenal pH 3-2 4-7 2-2 4-7 Fig. 3 Relationship between gastric emptying and Total minutes duodenal pH<4-0 40 0 90 0 intraduodenal after meals in patients with Zollinger- Lowest trypsin concentration flow (U/m1) 25 58 21 119 Ellison syndrome and in healthy controls. Each patient is Lowest lipase concentration identified by a different symbol. A symbol enclosed in a (U/ml) 10 381 1 532 circle indicates postoperative study.
Load more

Recommended publications
  • Endocrine Tumors of the Pancreas
    Friday, November 4, 2005 8:30 - 10:30 a. m. Pancreatic Tumors, Session 2 Chairman: R. Jensen, Bethesda, MD, USA 9:00 - 9:30 a. m. Working Group Session Pathology and Genetics Group leaders: J.–Y. Scoazec, Lyon, France Questions to be answered: 12 Medicine and Clinical Pathology Group leader: K. Öberg, Uppsala, Sweden Questions to be answered: 17 Surgery Group leader: B. Niederle, Vienna, Austria Questions to be answered: 11 Imaging Group leaders: S. Pauwels, Brussels, Belgium; D.J. Kwekkeboom, Rotterdam, The Netherlands Questions to be answered: 4 Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging ENETS Guidelines Neuroendocrinology 2004;80:394–424 Endocrine Tumors of the Pancreas - gastrinoma Epidemiology The incidence of clinically detected tumours has been reported to be 4-12 per million inhabitants, which is much lower than what is reported from autopsy series (about 1%) (5,13). Clinicopathological staging (12, 14, 15) Well-differentiated tumours are the large majority of which the two largest fractions are insulinomas (about 40% of cases) and non-functioning tumours (30-35%). When confined to the pancreas, non-angioinvasive, <2 cm in size, with <2 mitoses per 10 high power field (HPF) and <2% Ki-67 proliferation index are classified as of benign behaviour (WHO group 1) and, with the notable exception of insulinomas, are non-functioning. Tumours confined to the pancreas but > 2 cm in size, with angioinvasion and /or perineural space invasion, or >2mitoses >2cm in size, >2 mitoses per 20 HPF or >2% Ki-67 proliferation index, either non-functioning or functioning (gastrinoma, insulinoma, glucagonoma, somastatinoma or with ectopic syndromes, such as Cushing’s syndrome (ectopic ACTH syndrome), hypercaliemia (PTHrpoma) or acromegaly (GHRHoma)) still belong to the (WHO group 1) but are classified as tumours with uncertain behaviour.
    [Show full text]
  • Zollinger-Ellison Syndrome. Case Report
    https://doi.org/10.15446/cr.v5n1.71686 ZOLLINGER-ELLISON SYNDROME. CASE REPORT Keywords: Gastrinoma; Zollinger-Ellison Sydrome; Multiple Endocrine Neoplasia Type 1. Palabras clave: Gastrinoma; Síndrome de Zollinger-Ellison; Neoplasia endocrina múltiple tipo 1. Juan Felipe Rivillas-Reyes Juan Leonel Castro-Avendaño Universidad Nacional de Colombia - Sede Bogotá - Facultad de Medicina - Programa de Medicina - Bogotá D.C. - Colombia. Héctor Fabián Martínez-Muñoz Universidad Nacional de Colombia - Sede Bogotá - Facultad de Medicina - Departamento de Cirugía - Bogotá D.C. - Colombia. Corresponding author Juan Felipe Rivillas-Reyes. Facultad de Medicina, Universidad Nacional de Colombia. Bogotá D.C. Colombia. Email: [email protected]. Received: 13/04/2018 Accepted: 20/11/2018 zollinger-ellison syndrome ABSTRACT RESUMEN 29 Introduction: The Zollinger-Ellison syndrome Introducción. El síndrome de Zollinger-Elli- (ZES) is a pathology caused by a neuroendo- son (SZE) es una patología producida por un crine tumor, usually located in the pancreas tumor neuroendocrino habitualmente localiza- or the duodenum, which is characterized by do a nivel duodenal o pancreático, el cual pro- elevated levels of gastrin, resulting in an ex- duce niveles elevados de gastrina, derivando cessive production of gastric acid. en hipersecreción de ácido gástrico. Case presentation: A 42-year-old female Presentación del caso. Paciente femenino patient with a history of longstanding peptic de 42 años con antecedente de enfermedad ulcer disease, who consulted due to persistent ulceropéptica de larga data, quién consulta por epigastric pain, melena and signs of peritoneal epigastralgia persistente y deposiciones meléni- irritation. Perforated peptic ulcer was suspect- cas y presenta signos de irritación peritoneal. Se ed, requiring emergency surgical intervention.
    [Show full text]
  • Acute Diarrhea in Adults WENDY BARR, MD, MPH, MSCE, and ANDREW SMITH, MD Lawrence Family Medicine Residency, Lawrence, Massachusetts
    Acute Diarrhea in Adults WENDY BARR, MD, MPH, MSCE, and ANDREW SMITH, MD Lawrence Family Medicine Residency, Lawrence, Massachusetts Acute diarrhea in adults is a common problem encountered by family physicians. The most common etiology is viral gastroenteritis, a self-limited disease. Increases in travel, comorbidities, and foodborne illness lead to more bacteria- related cases of acute diarrhea. A history and physical examination evaluating for risk factors and signs of inflammatory diarrhea and/or severe dehydration can direct any needed testing and treatment. Most patients do not require labora- tory workup, and routine stool cultures are not recommended. Treatment focuses on preventing and treating dehydra- tion. Diagnostic investigation should be reserved for patients with severe dehydration or illness, persistent fever, bloody stool, or immunosuppression, and for cases of suspected nosocomial infection or outbreak. Oral rehydration therapy with early refeeding is the preferred treatment for dehydration. Antimotility agents should be avoided in patients with bloody diarrhea, but loperamide/simethicone may improve symptoms in patients with watery diarrhea. Probiotic use may shorten the duration of illness. When used appropriately, antibiotics are effective in the treatment of shigellosis, campylobacteriosis, Clostridium difficile,traveler’s diarrhea, and protozoal infections. Prevention of acute diarrhea is promoted through adequate hand washing, safe food preparation, access to clean water, and vaccinations. (Am Fam Physician. 2014;89(3):180-189. Copyright © 2014 American Academy of Family Physicians.) CME This clinical content cute diarrhea is defined as stool with compares noninflammatory and inflamma- conforms to AAFP criteria increased water content, volume, or tory acute infectious diarrhea.7,8 for continuing medical education (CME).
    [Show full text]
  • Gastrinoma: a Small Tumor with Big Symptoms
    Case Report ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.31.005159 Gastrinoma: A Small Tumor with Big Symptoms Hira Irfan1, Ahmed Imran Siddiqi1,2*, Waqas Shafiq1 and Umal Azmat1 1Department of Endocrinology, Shaukat Khanum memorial cancer hospital and research center, Lahore, Pakistan 2Department of Medicine Jersey General Hospital, Channel Islands UK *Corresponding author: Ahmed Imran Siddiqi, Department of Endocrinology, Shaukat Khanum memorial cancer hospital and research center, Lahore, Pakistan; Department of Medicine Jersey General Hospital, Channel Islands UK ARTICLE INFO ABSTRACT Received: November 04, 2020 Gastrinoma is rare gastrin secreting tumor and can be challenging to diagnose in the Published: November 11, 2020 absence of typical clinical features. Surgical resection remains the mainstay of treatment and can be curative, but the clinical presentation can compromise complete resection especially if the disease has already metastasized. We present here a 77-year-old lady Citation: Hira Irfan, Ahmed Imran Siddiqi, with abdominal pain and secretory diarrhea. Gastrinoma was diagnosed in a stepwise approach of investigations and then surgically removed. Following surgery, the patient Small Tumor with Big Symptoms. Biomed got prescribed octreotide for complete resolution of symptoms. Conservative treatment JWaqas Sci &Shafiq, Tech Umal Res Azmat.31(5)-2020. Gastrinoma: BJSTR. A is only recommended for patients unsuitable for surgery, with widespread metastasis and MS.ID.005159. on patients’ own choice. Abbreviations: NET: Neuroendocrine Tumors; ZES: Zollinger-Ellison Syndrome; MEN-1: Multiple Endocrine Neoplasia Type-1; SSTRs: Somatostatin Receptors; PTH: Parathyroid Hormone Introduction for a Gastrinoma (5). We report here a case of a 77-year-old lady Gastrinomas are functional neuroendocrine tumors (NET) diagnosed with a Gastrinoma.
    [Show full text]
  • A Review of Normal Function and Role of Gastrin in Zollinger-Ellison
    When Gastrin Goes Awry: A Review of Normal Function and Role of Gastrin in Zollinger-Ellison Syndrome Leigha LaTourette1, Janel Cross2, Barbara Brabetz2 Department of Plant and Animal Science1, Department of Natural Sciences and Mathematics2 Introduction Gastrin: Normal Mode of Action Gastrin’s Role in Zollinger-Ellison Syndrome MEN 1 & ZES Gastrin is a digestive hormone that acts on the MEN1 is an inheritable disease that causes over neuroendocrine and parietal cells of the secretion of hormones via tumors on the gastrointestinal tract to ultimately secrete gastric endocrine glands throughout the body.4 Around a acid. Gastrin secretion begins even before food 30% of these tumors are found to be malignant. is consumed, as the mere anticipation of a meal ZES is commonly associated with the MEN1 due can lead to a series of events ending in the to the presence of tumors found in the stomach creation of the gastric acid needed to breakdown and small intestine.4 These gastrointestinal foods. Not only does Gastrin support the tumors caused by MEN 1 give the person a digestion of foods, but it also stimulates growth, higher likelihood of contracting ZES, as the secretion, blood flow, and acts as a defense probability of having pancreatic or duodenal mechanism against bacteria in the tumors is increased.4 gastrointestinal system. When the production of Gastrin becomes overt, major consequences like that of Zollinger Ellison Syndrome (ZES). ZES is an extremely rare disease occurring in people between the ages of 30-60.4 ZES is related to the uncontrolled secretion of gastrin due to the presence of certain pancreatic or duodenal tumors.
    [Show full text]
  • Benign Oesophageal Stricture and Chronic Diarrhoea As Atypical
    Open Access Case Report DOI: 10.7759/cureus.16593 Benign Oesophageal Stricture and Chronic Diarrhoea As Atypical Presenting Symptoms of an Advanced Metastatic Pancreatic Gastrinoma: A Case Report and Review of Literature Muhammad Hafiz Kamarul Bahrin 1 , Raoof Hagag 2 , Abuobeida Ali 3 , Seifeldin Yahia 4 , Richard Armstrong 5 1. Gastroenterology, United Lincolnshire Hospitals Trust, Boston, GBR 2. Acute Medicine, United Lincolnshire Hospitals National Health Service (NHS) Trust, Boston, GBR 3. Gastroenterology, Peterborough City Hospital, Peterborough, GBR 4. Diabetes and Endocrinology, United Lincolnshire Hospitals National Health Service (NHS) Trust, Boston, GBR 5. Gastroenterology, United Lincolnshire Hospitals National Health Service (NHS) Trust, Boston, GBR Corresponding author: Muhammad Hafiz Kamarul Bahrin, [email protected] Abstract Gastrinoma or otherwise known as Zollinger-Ellison syndrome is characterised by hypersecretion of gastrin and gastric acid leading to the formation of recurrent atypical ulcers along the upper gastrointestinal tract. It is extremely difficult to diagnose during an acute presentation both due to its rarity and its lack of pathognomonic symptoms. Its symptoms range from mild to severe to life-threatening and often get mistaken for a different condition such as viral gastroenteritis as seen in our case report. The most common symptoms of gastrinoma include abdominal pain, dyspepsia and chronic diarrhoea. It rarely presents as a benign oesophageal stricture with some case series reporting the frequency to be as low as 0.4%. Our literature review of 9 random case reports on gastrinoma/Zollinger-Ellison syndrome selected from Pubmed Central reviewed the frequency of its presenting symptoms and investigation modalities involved throughout its diagnostic process. In summary, it agrees with the findings postulated by Jensen’s series.
    [Show full text]
  • GASTRIC CANCER STRUCTURED REPORTING PROTOCOL (2Nd Edition, 2020)
    GASTRIC CANCER STRUCTURED REPORTING PROTOCOL (2nd Edition, 2020) Incorporating the: International Collaboration on Cancer Reporting (ICCR) Carcinoma of the Stomach Dataset www.ICCR-Cancer.org Core Document versions: • ICCR dataset: Carcinoma of the Stomach 1st edition • AJCC Cancer Staging Manual 8th edition • Digestive System Tumours, World Health Organization Classification of Tumours, 5th Edition, Volume 1, 2019 ii Gastric Cancer Structured Reporting Protocol 2nd edition ISBN: 978-1-76081-425-0 Publications number (SHPN): (CI) 200282 Online copyright © RCPA 2020 This work (Protocol) is copyright. You may download, display, print and reproduce the Protocol for your personal, non-commercial use or use within your organisation subject to the following terms and conditions: 1. The Protocol may not be copied, reproduced, communicated or displayed, in whole or in part, for profit or commercial gain. 2. Any copy, reproduction or communication must include this RCPA copyright notice in full. 3. With the exception of Chapter 6 - the checklist, no changes may be made to the wording of the Protocol including any Standards, Guidelines, commentary, tables or diagrams. Excerpts from the Protocol may be used in support of the checklist. References and acknowledgments must be maintained in any reproduction or copy in full or part of the Protocol. 4. In regard to Chapter 6 of the Protocol - the checklist: o The wording of the Standards may not be altered in any way and must be included as part of the checklist. o Guidelines are optional and those which are deemed not applicable may be removed. o Numbering of Standards and Guidelines must be retained in the checklist, but can be reduced in size, moved to the end of the checklist item or greyed out or other means to minimise the visual impact.
    [Show full text]
  • Neuroendocrine TUMORS
    NeuroendocrinE This book provides you with five informative chapters These chapters guide the clinician through: • Diagnosing and Treating Gastroenteropancreatic Tumors, Including ICD-9 Codes TumorS • Clinical Presentations and Their Syndromes, Including ICD-9 Codes Diagnosis and Management Diagnosis A Comprehensive Guide to to Guide A Comprehensive NeuroendocrinE The remaining three chapters guide the clinician through the selection of appropriate assays, profiles, and dynamic challenge protocols for diagnosing and monitoring neuroendocrine symptoms. TumorS • Assays, Including CPT Codes A Comprehensive Guide to • Profiles, Including CPT Codes • Dynamic Challenge Protocols, Including CPT Codes Diagnosis and Management Inter Science Institute Inter Science Institute 944 West Hyde Park Boulevard Inglewood, California 90302 (800) 255-2873 (800) 421-7133 (310) 677-3322 Vinik Aaron I. Vinik, MD, PhD Eugene A. Woltering, MD Fax (310) 677-2846 www.interscienceinstitute.com Woltering Thomas M. O’Dorisio, MD Vay Liang W. Go, MD O’Dorisio Go Inter Science Institute GI Council Chairman Eugene A. Woltering, MD, FACS The James D. Rives Professor of Surgery and Neurosciences Chief of the Sections of Surgical Endocrinology and Oncology Director of Surgery Research The Louisiana State University Health Sciences Center New Orleans, Louisiana Executive Members Aaron I. Vinik, MD, PhD, FCP, MACP Professor of Medicine, Pathology and Neurobiology Director of Strelitz Diabetes Research Institute Eastern Virginia Medical School Norfolk, Virginia Vay Liang W.
    [Show full text]
  • Mn 02-104 Deol Q.Qxd
    CASE REPORT Solitary Hepatic Gastrinoma Treated With Laparoscopic Radiofrequency Ablation Zöe K. Deol, MD, Eldo Frezza, MD, Steven DeJong, MD, Jack Pickleman, MD ABSTRACT INTRODUCTION Background: This is a case of a solitary hepatic gastri- The annual incidence of the 2 most common neuroen- noma in a 65-year-old male. The patient was diagnosed docrine tumors, insulinoma and gastrinoma, is about 1 with Zollinger-Ellison syndrome in 1991. He had nega- per million.1 Although insulinomas are usually benign, tive radiologic and surgical explorations at that time. He 60% to 80% of gastrinomas are malignant. Hepatic or was maintained on proton-pump inhibitors for the next nodal metastases are found in 60% of patients diagnosed 10 years without symptoms. with Zollinger-Ellison syndrome (ZES).2 Long-term (5- year) survival of patients with resected extrahepatic gas- Methods: A computed tomographic (CT) scan done in trinoma is 95%.3 This number is decreased to 85% in April 2001 demonstrated a 5-cm right hepatic lesion. patients with resected hepatic metastases.4 However, 5- Radionucleotide scanning with octreotide demonstrated year survival in patients with unresected hepatic gastri- intense activity in the same area in the right hepatic lobe. noma is a dismal 30%.2,5,6 Hepatic resection continues to His serum gastrin was 317 pg/mL. He underwent laparo- be an effective treatment for a solitary hepatic gastrino- scopic radiofrequency ablation of the lesion. ma.2 Other methods have been tried in patients with Results: Treatment resulted in a 6-cm ablative area giv- tumor locations or medical problems prohibiting major ing a 1-cm margin on the tumor.
    [Show full text]
  • Specific and Non-Specific Biomarkers in Neuroendocrine
    cancers Review Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors Andrea Sansone 1 , Rosa Lauretta 2, Sebastiano Vottari 3, Alfonsina Chiefari 3, Agnese Barnabei 3 , Francesco Romanelli 1 and Marialuisa Appetecchia 3,* 1 Section of Medical Pathophysiology, Food Science and Endocrinology, Dept. of Experimental Medicine, Sapienza University of Rome, 00165 Rome, Italy 2 Internal Medicine, Angioloni Hospital, San Piero in Bagno, 47026 Forlì-Cesena, Italy 3 Endocrinology Unit, Regina Elena National Cancer Institute IRCCS, Rome 00144, Italy * Correspondence: [email protected] Received: 3 July 2019; Accepted: 2 August 2019; Published: 4 August 2019 Abstract: The diagnosis of neuroendocrine tumors (NETs) is a challenging task: Symptoms are rarely specific, and clinical manifestations are often evident only when metastases are already present. However, several bioactive substances secreted by NETs can be included for diagnostic, prognostic, and predictive purposes. Expression of these substances differs between different NETs according to the tumor hormone production. Gastroenteropancreatic (GEP) NETs originate from the diffuse neuroendocrine system of the gastrointestinal tract and pancreatic islets cells: These tumors may produce many non-specific and specific substances, such as chromogranin A, insulin, gastrin, glucagon, and serotonin, which shape the clinical manifestations of the NETs. To provide an up-to-date reference concerning the different biomarkers, as well as their main limitations, we reviewed and summarized existing literature. Keywords: neuroendocrine tumors; biomarkers; gastroenteropancreatic tumors; prognostic markers; diagnosis 1. Introduction Neuroendocrine tumors (NETs) are a heterogeneous group of rare malignancies which, from a clinical point of view, represent a true challenge for clinicians at all stages of the disease.
    [Show full text]
  • Patterns of GI Tract Injury
    Adapted/inspired by: Atlas of Gastrointestinal Pathology. Arnold et al. 2015 Prepared by Kurt Schaberg Last updated: 4/2/2020 Patterns of GI Tract Injury Esophagus Non-keratinizing stratified Normal Esophagus squamous mucosa Benign Incidental Findings: Gastric “Inlet Patch”- Heterotopic Muscularis mucosae gastric mucosa in esophagus Esophageal duct Pancreatic Heterotopia/Metaplasia Glycogenic Acanthosis – Epithelial Submucosal glands hyperplasia with abundant, enlarged superficial glycogenated cells; clinically appears white (Muscularis propria: distal = smooth muscle; proximal = skeletal muscle) Acute Esophagitis Intraepithelial Neutrophils with Erosion/Ulceration GERD Often scattered Eos (usu. < 15/HPF), Intercellular edema, Basal cell hyperplasia, Elongation of vascular papilla. Worse distally (near GEJ). Ulcer! Infections Candida - Look for fungal hyphae, Get PAS-D/GMS HSV - Look for Molding, Multinucleation, Margination in epithelial cells. CMV – Look for inclusions in mesenchymal cells. Medications (“Pill esophagitis”) Look for crystals, resins, and pill fragments; Polarize to help looking for foreign material. Eosinophilic Esophagitis Increased intraepithelial Eosinophils (report per HPF) GERD Eos typically < 15/HPF, Intraepithelial T lymphocytes (“squiggle cells”), Intercellular edema, Basal cell hyperplasia, Elongation of vascular papilla. Worse distally (near GEJ). Eosinophilic Esophagitis Typically >20 Eos/HPF. Often eosinophilic microabscesses with degranulation. Often diffuse or worse proximally. Associated with “Atopic Triad”
    [Show full text]
  • Surgical Management of Zollinger-Ellison Syndrome; State of the Art
    Surgical Management of Zollinger-Ellison Syndrome; State of the Art Ellen H. Morrow, MD, JeffreyA. Norton, MD* KEYWORDS Gastrinoma Surgery Diagnosis Localization Outcome MEN-1 Zollinger-Ellison Syndrome (ZES) was originally described in 1955.1 It is a syndrome of acid hypersecretion caused by a gastrin-producing tumor (gastrinoma). Since the recognition of this disease entity, diagnosis and treatment strategies have changed greatly. The purpose of this review is to describe the current standard in diagnosis and surgical management of ZES and to outline some controversies that have arisen recently. EPIDEMIOLOGY The incidence of ZES in the United States is one to three new cases per million per year, making it a rare condition.2 Eighty percent of gastrinomas occur sporadically, while 20% are associated with Multiple Endocrine Neoplasia Type 1 (MEN-1).3 ZES causes 0.1% to 1% of peptic ulcer disease.4 Men are slightly more likely to develop ZES.5 The mean age at which symptoms begin is 41 years.6 Patients with MEN-1– associated ZES are likely to present at a younger age; in the third decade of life.7 ZES occurs in approximately 25% of patients with MEN-1.8 PRESENTATION The presenting signs and symptoms of ZES have also changed with earlier recognition and diagnosis. Initially, it was described as gastric acid hypersecretion, ulcers in unusual locations (jejunum), recurrent ulcers, and nonbeta islet cell tumors of the pancreas.9 Subsequent studies of large numbers of patients with ZES have demonstrated that common presenting symptoms include abdominal pain, diarrhea, heartburn, nausea, and weight loss.6 Diarrhea is a common problem as approximately 80% of patients Division of General Surgery, Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive, H3591, Stanford, CA 94305-5641, USA * Corresponding author.
    [Show full text]